Objectives: Basic science studies of ureteral physiology and pathophysiology are commonly performed on animal ureters due to several limitations associated with human ureteral sampling. In this work we question whether animal ureters are good replicas of human ureteral behavior for pharmacological studies. Materials and Methods: Ureteral rings from human, porcine and ovine ureters underwent the same organ bath protocol. After stimulation with KCl, ureters were subjected to different doses of vardenafil. Basic contractility and ureteral response to vardenafil were analyzed. Results: A different pattern of basic contractility was evidenced between species. Vardenafil administration induced a dose-dependent reduction in KCl-induced amplitude increase in human ureters and a dose-dependent reduction in autonomic contractile rhythm of porcine and ovine ureters. Although animal ureters could predict the relaxant response of human samples to vardenafil, its effect would have been overestimated using only animal models. Conclusions: Human ureteral investigations cannot entirely be replaced by existing animal models since results of the latter will vary significantly according to the tested pharmaceutical agent.

Keywords:
Vardenafil, Human, Porcine, Ovine, Organ bath, Ureteral contractility
1.
Gratzke C, Uckert S, Kedia G, et al: In vitro effects of PDE5 inhibitors sildenafil, vardenafil and tadalafil on isolated human ureteral smooth muscle: a basic research approach. Urol Res 2007;35:49-54.
2.
Al-Aown A, Kyriazis I, Kallidonis P, et al: Vardenafil effect on ureteric smooth muscle: in vitro study in porcine model. J Endourol 2011;25:505-509.
3.
Seitz C, Liatsikos E, Porpiglia F, et al: Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol 2009;56:455-471.
4.
Yakoubi R, Lemdani M, Monga M, et al: Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 2011;186:928-934.
5.
Zhu Y, Duijvesz D, Rovers MM, et al: alpha-Blockers to assist stone clearance after extracorporeal shock wave lithotripsy: a meta-analysis. BJU Int 2010;106:256-261.
6.
Kühn R, Uckert S, Stief CG, et al: Relaxation of human ureteral smooth muscle in vitro by modulation of cyclic nucleotide-dependent pathways. Urol Res 2000;28:110-115.
7.
Saighi D, Zerbib M, Thiounn N, et al: In vitro study of the modulation of human ureteral tonus by nitric oxide and zaprinast, a phosphodiesterase inhibitor. Prog Urol 2000;10:1161-1168.
8.
Wolf JS Jr, Humphrey PA, Rayala HJ, et al: Comparative ureteral microanatomy. J Endourol 1996;10:527-531.
9.
Santis WF, Peters CA, Yalla SV, et al: Ureteral function is modulated by a local renin-angiotensin system. J Urol 2003;170:259-263.
10.
Nakada SY, Jerde TJ, Bjorling DE, et al: Selective cyclooxygenase-2 inhibitors reduce ureteral contraction in vitro: a better alternative for renal colic? J Urol 2000;163:607-612.
11.
Chaignat V, Danuser H, Stoffel MH: Effects of a non-selective COX inhibitor and selective COX-2 inhibitors on contractility of human and porcine ureters in vitro and in vivo. Br J Pharmacol 2008;154:1297-1307.
12.
Lowry PS, Jerde TJ, Bjorling DE, et al: Obstruction alters the effect of prostaglandin E2 on ureteral contractility. J Endourol 2005;19:183-187.
13.
Sivrikaya A, Celik OF, Sivrikaya N, et al: The effect of diclofenac sodium and papaverine on isolated human ureteric smooth muscle. Int Urol Nephrol 2003;35:479-483.
14.
Weiss R, Mevissen M, Hauser DS, et al: Inhibition of human and pig ureter motility in vitro and in vivo by the K(+) channel openers PKF 217-744b and nicorandil. J Pharmacol Exp Ther 2002;302:651-658.
15.
Lee SY, Lee MY, Park SH, et al: NS-398 (a selective cyclooxygenase-2 inhibitor) decreases agonist-induced contraction of the human ureter via calcium channel inhibition. J Endourol 2010;24:1863-1868.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.